Inhibition of LC3A expression using siRNA also decreased LC3B-II levels and cell proliferation, whereas a 5-azadC treatment restored LC3A expression in lung cancer PC9 cells and decreased their response to EGFR-TKI. Here, MAP1LC3A is linked to lung cancer.